These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34148673)

  • 1. [Which adjuvant measures should be associated with long-term oral corticosteroid therapy in inflammatory diseases? A summary of existing French recommendations].
    Hoefsloot S; Urbanski G; Lacout C; Bouvard B; Lavigne C
    Rev Med Interne; 2021 Sep; 42(9):616-624. PubMed ID: 34148673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term systemic corticosteroid-therapy associated measures: description of the French internal medicine physicians' practices].
    Fardet L; Hanslik T; Blanchon T; Perdoncini-Roux A; Kettaneh A; Tiev KP; Turbelin C; Dorleans Y; Cabane J
    Rev Med Interne; 2008 Dec; 29(12):975-80. PubMed ID: 18501996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty.
    Buckley LM; Marquez M; Hudson JO; Downs RW; Vacek P; Small RE; Poses R
    J Rheumatol; 1998 Nov; 25(11):2195-202. PubMed ID: 9818664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is enough attention being given to the adverse effects of corticosteroid therapy?
    Hougardy DM; Peterson GM; Bleasel MD; Randall CT
    J Clin Pharm Ther; 2000 Jun; 25(3):227-34. PubMed ID: 10886467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Association between prescription of long-term systemic glucocorticoid therapy associated measures and prescriber's medical speciality].
    Six M; Morin C; Fardet L
    Rev Med Interne; 2019 Jul; 40(7):427-432. PubMed ID: 30683427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Description of French general practitioners' practices regarding long term systemic corticosteroid therapy-associated measures].
    Perdoncini-Roux A; Blanchon T; Hanslik T; Lasserre A; Turbelin C; Dorleans Y; Cabane J; Fardet L
    Rev Prat; 2009 Oct; 59(8 Suppl):19-24. PubMed ID: 19916281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid-induced osteoporosis.
    Joseph JC
    Am J Hosp Pharm; 1994 Jan; 51(2):188-97; quiz 229-30. PubMed ID: 8160669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Corticosteroid-induced osteoporosis].
    El Maghraoui A
    Presse Med; 2004 Oct; 33(17):1213-7. PubMed ID: 15523293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of corticosteroid-induced osteoporosis.
    Drug Ther Bull; 2010 Sep; 48(9):98-101. PubMed ID: 20810708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid osteoporosis: practical implications of recent trials.
    Sambrook PN
    J Bone Miner Res; 2000 Sep; 15(9):1645-9. PubMed ID: 10976984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doctors' beliefs and knowledge on corticosteroid-induced osteoporosis: identifying barriers to improve prevention.
    Duyvendak M; Naunton M; van Roon EN; Brouwers JR
    J Clin Pharm Ther; 2011 Jun; 36(3):356-66. PubMed ID: 21545615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists.
    Soucy E; Bellamy N; Adachi JD; Pope JE; Flynn J; Sutton E; Campbell J
    J Rheumatol; 2000 Jun; 27(6):1506-12. PubMed ID: 10852279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the prescription of long-term systemic steroid-therapy associated measures].
    Lamchahab FE; Reffas W; Bouattar T; Abdellaoui EK; Ouzeddoun N; Bayahia R; Aouni A; El Fassi Fihri T; Senouci K; Ait Ourhroui M; Hassam B
    Ann Pharm Fr; 2012 Sep; 70(5):292-7. PubMed ID: 23020920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical practice guideline: drug therapy for corticosteroid-induced osteoporosis].
    Agence française de sécurité sanitaire des produits de santé
    Rev Mal Respir; 2004 Feb; 21(1):185-9. PubMed ID: 15260060
    [No Abstract]   [Full Text] [Related]  

  • 15. Steroid-induced osteoporosis. Are your asthmatic patients at risk?
    Niewoehner CB; Niewoehner DE
    Postgrad Med; 1999 Mar; 105(3):79-83, 87-8, 91. PubMed ID: 10086035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corticosteroid use in autoimmune blistering diseases.
    Frew JW; Murrell DF
    Dermatol Clin; 2011 Oct; 29(4):535-44. PubMed ID: 21924995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates.
    Ringe JD; Farahmand P
    Clin Rheumatol; 2007 Apr; 26(4):474-84. PubMed ID: 17122953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticosteroid-induced osteoporosis prevention: longitudinal practice patterns in The Netherlands 2001-2005.
    Duyvendak M; Naunton M; Atthobari J; van den Berg PB; Brouwers JR
    Osteoporos Int; 2007 Oct; 18(10):1429-33. PubMed ID: 17323108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of corticosteroid-induced osteoporosis: results of a patient survey.
    Buckley LM; Marquez M; Feezor R; Ruffin DM; Benson LL
    Arthritis Rheum; 1999 Aug; 42(8):1736-9. PubMed ID: 10446875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticosteroid-induced osteoporosis: a guide to optimum management.
    Cranney A; Adachi JD
    Treat Endocrinol; 2002; 1(5):271-9. PubMed ID: 15832482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.